Failure of G-CSF therapy in neutropenia associated with Sjögren's syndrome.
Vivancos
J
J
Vila
M
M
Serra
A
A
Loscos
J
J
Anguita
A
A
D000583:Amikacin / Q000627:therapeutic use; D000740:Anemia / Q000139:chemically induced*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D000077731:Meropenem; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000188:drug therapy / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D011994:Recombinant Proteins; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy*; D013845:Thienamycins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced*; D017211:Treatment Failure
D000900:Anti-Bacterial Agents; D011994:Recombinant Proteins; D013845:Thienamycins; D016179:Granulocyte Colony-Stimulating Factor; D000583:Amikacin; D000077731:Meropenem; D000069585:Filgrastim; D011241:Prednisone